Bioceres Crop Solutions Corp SC TO-I/A, filed Aug 25, 2020
Bioceres Crop Solutions Corp. (BIOX)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 4
to
SCHEDULE TO
(Rule 14d-100)
Tender
Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
BIOCERES
CROP SOLUTIONS CORP.
(Name of Subject Company (Issuer) and Name of Filing Person (Issuer))
Warrants to Purchase Ordinary Shares
(Title of Class of Securities)
G1117K106*
(CUSIP Number of Public Warrants)
Amendment No. 4
to
SCHEDULE 13E-3
RULE 13E-3 TRANSACTION STATEMENT
UNDER SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934
BIOCERES
CROP SOLUTIONS CORP.
(Name of Subject Company (Issuer))
BIOCERES CROP SOLUTIONS CORP.
BIOCERES LLC
BIOCERES S.A.
(Name of Filing Person(s))
Warrants to Purchase Ordinary Shares
(Title of Class of Securities)
G1117K106
(CUSIP Number of Public Warrants)
Federico Trucco
Chief Executive Officer
Bioceres Crop Solutions Corp.
Ocampo 210 bis, Predio CCT, Rosario
Province of Santa Fe, Argentina
Phone: +54-341-4861122
(Name, Address and
Telephone Number of Person
Authorized to Receive Notices and Communications on Behalf of Filing Persons)
with a copy to:
Matthew S. Poulter, Esq.
Peter Cohen-Millstein, Esq.
Linklaters LLP
1345 Avenue of the Americas
New York, New York 10105
(212) 903-9000
CALCULATION OF FILING FEE
| Transaction valuation** | Amount of filing fee |
| $3,509,000 | $455.47 |
| * | The warrants of Bioceres Crop Solutions Corp. (the “Company”) that are publicly traded have a CUSIP number of G1117K106. The CUSIP number for the Company’s ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), is G1117K114. |
| ** | Estimated for purposes of calculating the amount of the filing fee only, in accordance with Rule 0-11(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company is offering holders of 24,200,000 of the Company’s warrants (the “Warrants”) the opportunity to exchange such Warrants for either 0.12 of the Company’s Ordinary Shares or $0.45 in cash per Warrant, without interest, at the election of the holder. The amount of the filing fee assumes that all outstanding Warrants will be exchanged and is calculated pursuant to Rule 0-11(b) of the Exchange Act, which equals $129.80 for each $1,000,000 of the value of the transaction. The transaction value was determined by using the average of the high and low prices of the publicly traded Warrants as reported on the NYSE American (the “NYSE”) on July 24, 2020, which was $0.145. |
| ¨ | Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| Amount Previously Paid: N/A | Filing Party: N/A | |
| Form or Registration No.: N/A | Date Filed: N/A |
| ¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
| ¨ | third-party tender offer subject to Rule 14d-1. | |
| x | issuer tender offer subject to Rule 13e-4. | |
| x | going-private transaction subject to Rule 13e-3. | |
| ¨ | amendments to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: x
INTRODUCTION
This Amendment No. 4 (this “Amendment”) amends and supplements the Tender Offer Statement and Schedule 13E-3 Transaction Statement on Schedule TO (together with any subsequent amendments and supplements thereto, the “Schedule TO”), originally filed with the Securities and Exchange Commission by Bioceres Crop Solutions Corp. (the “Company” or “BIOX” or “we”, “us” or “our”), Bioceres LLC and Bioceres S.A. pursuant to Rule 13e-3 and, solely with respect to the Company, Rule 13e-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on July 27, 2020. The Schedule TO relates to the offer to exchange any and all of the Company’s 24,200,000 outstanding warrants (the “Warrants”), each of which is exercisable for one share of the Company’s ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), for either 0.12 Ordinary Shares (the “Exchange Shares”) or $0.45 in cash per Warrant, without interest (the “Cash Consideration”, and together with the Exchange Shares, the “Exchange Consideration”), at the election of the holder. The Company’s offer is being made upon the terms and subject to certain conditions set forth in the Offer to Exchange, dated July 27, 2020 (the “Offer to Exchange”), a copy of which is filed was filed as Exhibit (a)(1)(A) to the Schedule TO, and in the related Letter of Election and Transmittal (the “Letter of Election and Transmittal”), a copy of which was filed as Exhibit (a)(1)(E) to the Schedule TO, which, as amended or supplemented from time to time, together constitute the offer (the “Offer”).
This is the final amendment to the Schedule TO and is being filed to report the results of the Offer. This Amendment No. 4 to the Schedule TO, as it amends and supplements the Schedule TO, is intended to satisfy the reporting requirements of a Tender Offer Statement on Schedule TO of BIOX, a Schedule 13E-3 Transaction Statement of BIOX, a Schedule 13E-3 Transaction Statement of Bioceres LLC and a Schedule 13E-3 Transaction Statement of Bioceres S.A. pursuant to Rule 13e-4(c)(2) and Rule 13e-3(d)(1) under the Exchange Act.
All information in the Offer to Exchange is incorporated by reference in response to all of the items in the Schedule TO, and is supplemented only by those items specifically provided in this Amendment.
This Amendment should be read in conjunction with the Schedule TO, the Offer to Exchange and the related Letter of Election and Transmittal, as the same may be further amended or supplemented hereafter and filed with the SEC.
Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment.
2
Items 1 through 11 and Item 13.
The information set forth under these Items of the Schedule TO is hereby supplemented by adding the following:
| 1. | The Offer expired at 11:59 P.M., New York City time, at the end of the day on August 24, 2020. Based upon information provided by Continental Stock Transfer & Trust Company, the depositary for the Offer, Offer, a total of 21,938,774 Warrants were validly tendered and not properly withdrawn prior to the expiration of the Offer. The Company accepted for exchange all such Warrants and will pay an aggregate amount of approximately $115,062 of the Cash Consideration and issue an aggregate of 2,601,954 Exchange Shares in exchange for the Warrants tendered. |
On August 25, 2020, the Company issued a press release announcing the final results of the Offer as set forth above. A copy of the press release is filed as Exhibit (a)(5)(E) to the Schedule TO and is incorporated herein by reference.
Item 12. Exhibits.
| 1. | Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit: |
|
Exhibit |
Description | |
| (a)(5)(E) | Press Release, dated August 25, 2020, announcing the results of the exchange offer. |
| * | Filed herewith. |
3
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: August 25, 2020
| Bioceres Crop Solutions Corp. | ||
| By: | /s/ Federico Trucco | |
|
Name: Federico Trucco Title: Chief Executive Officer |
| Bioceres LLC | ||
| By: | /s/ Gloria Montaron Estrada | |
|
Name: Gloria Montaron Estrada Title: Manager |
| Bioceres S.A. | ||
| By: | /s/ Gloria Montaron Estrada | |
|
Name: Gloria Montaron Estrada Title: Attorney-in-fact |
4
EXHIBIT INDEX
5
| (d)(6)** | Rizobacter Shareholders Agreement, dated as of March 5, 2019, by and among Bioceres LLC, Pedro Enrique Mac Mullen, María Marta Mac Mullen and International Property Services Corp. (Incorporated by reference to Exhibit 2.4 to the Company’s Form 20-F (File No. 001-38836), filed with the SEC on March 14, 2019). | |
| (e) | Not applicable. | |
| (f) | Not applicable. | |
| (g) | Not applicable. | |
| (h) | Not applicable. |
| * | Filed herewith. |
| ** | Previously filed. |
6
Exhibit (a)(5)(E)
BIOCERES CROP SOLUTIONS CORP. ANNOUNCES
SUCCESSFUL COMPLETION OF OFFER TO EXCHANGE OUTSTANDING WARRANTS
Rosario, Argentina – August 25, 2020 – Bioceres Crop Solutions Corp. (“Bioceres” or the “Company”) (NYSE American: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, today announced the successful completion of its previously announced offer to exchange any and all of its 24,200,000 outstanding warrants (the “Warrants”), for either 0.12 Ordinary Shares (the “Exchange Shares”) or $0.45 in cash per Warrant, without interest (the “Cash Consideration”, and together with the Exchange Shares, the “Exchange Consideration”), at the election of the holder (the “Offer”). The Offer was made upon the terms and subject to the conditions set forth in the Company’s Tender Offer Statement and Schedule 13E-3 Statement on Schedule TO, originally filed by the Company with the Securities and Exchange Commission (the “SEC”) on July 27, 2020, as amended and supplemented by (1) Amendment No. 1 filed by the Company with the SEC on August 6, 2020, (2) Amendment No. 2 filed by the Company with the SEC on August 10, 2020 and (3) Amendment No. 3 filed by the Company with the SEC on August 13, 2020 (the “Schedule TO”), and the related letter of election and transmittal and other offer materials. The Offer expired at 11:59 P.M., New York City time, on August 24, 2020.
Based on information provided by Continental Stock Transfer & Trust Company, the depositary for the Offer, a total of 21,938,774 Warrants were validly tendered and not properly withdrawn prior to the expiration of the Offer. The Company accepted for exchange all such Warrants and will pay an aggregate amount of approximately $115,062 of the Cash Consideration and issue an aggregate of 2,601,954 Exchange Shares in exchange for the Warrants tendered. Delivery of the Exchange Consideration will be made promptly.
As disclosed in the Schedule TO filed with the SEC on July 27, 2020, the Company will promptly redeem the 2,261,226 Warrants that were not validly tendered or exchanged pursuant to the Offer for $0.405 in cash per Warrant. Following the redemption of Warrants not validly tendered, ordinary shares of the Company will be the only listed security available for trading with a total of 38,691,041 ordinary shares outstanding after the issuance of the Exchange Shares.
The Offer was made pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) contained in Section 3(a)(9) of the Securities Act. The Company has not filed and will not file a registration statement under the Securities Act or any other federal or state securities laws with respect to the Offer.
Innisfree M&A Incorporated acted as the information agent for the Offer and the depositary for the Offer is Continental Stock Transfer & Trust Company. For questions and information, please call the information agent toll free at (877) 456-3402 (banks and brokers can call collect at (212) 750-5833).
Additional Information and Where to Find It
This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any of the Company’s Warrants. The Offer described above was only made pursuant to the offer to exchange, the related letter of election and transmittal and other Offer materials included as exhibits to the Schedule TO filed with the SEC on July 27, 2020. The Schedule TO (including the offer to exchange, related letter of election and transmittal and other Offer materials) contains important information about the Offer that should be read carefully. These materials were distributed free of charge to all Warrant holders. In addition, these materials (and all other materials filed by Bioceres with the SEC) are available at no charge from the SEC through its website at www.sec.gov. Warrant holders may also obtain free copies of the documents by directing a request to the information agent at 501 Madison Avenue, 20th floor, New York, New York 10022. Warrant holders are urged to read the Offer documents and the other relevant materials because they contain important information about the Offer.
1
Exhibit (a)(5)(E)
About Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp. (NYSE American: BIOX) is a fully-integrated global provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. The Company’s solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers’ decisions and provide end-to-end traceability for production outputs. For more information, visit https://investors.biocerescrops.com.
Forward Looking Statements
This press release includes “forward-looking statements” regarding Bioceres, its financial condition and anticipated activities that reflect the Company’s views and information currently available. This information is, where applicable, based on estimates, assumptions and analysis that Bioceres believes, as of the date hereof, provide a reasonable basis for the information contained herein. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “aim”, “estimate”, “target”, “anticipate”, “believe”, “continue”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding Bioceres’ plans, activities, events, strategies, objectives, targets and expected financial performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Bioceres and its respective officers, employees, agents or associates and, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, clients and the Company, on our business, financial condition, liquidity position and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (1) the number of Warrant holders that respond and elect to participate in the Offer, (2) Bioceres’ ability to recognize the anticipated benefits of the Offer; (3) changes in applicable laws or regulations, including those that pertain to tender and exchange offers; (4) the possibility that Bioceres may be materially adversely affected by other economic, business, and/or competitive factors; and (5) other risks and uncertainties indicated from time to time in the most recent Annual Report on Form 20-F for the fiscal year ended June 30, 2019, as amended, and any other filings updated from time to time which can be found at the SEC’s website, www.sec.gov.
— Source: Bioceres Crop Solutions Corp. —
Investor Relations Contact:
Maximo Goya
Tel: +54-341-4861100
Email: maximo.goya@biocerescrops.com
2